6种天然药物对人眼晶状体上皮细胞增殖及迁移抑制作用的比较

摘要

目的：观察白藜芦醇（Resveratrol）、叶黄素（Lutein）、苦参碱（Matrine）、原花青素（Proanthocyanidin）、姜黄素（Curcumin）、β‐榄香烯（β‐Elemene）抑制人晶状体上皮细胞（SRA01／04）增殖和迁移的作用，并比较它们抑制该细胞增殖及迁移作用的强弱。方法采用CCK‐8法及划痕实验初步定量分析比较各药物对SRA01／04细胞增殖和迁移的影响。结果通过CCK‐8实验证实，6种天然药物均可显著抑制bFGF诱导的SRA01／04的增殖（均 P＜0.05），且6种药物抑制bFGF诱导的细胞增殖作用由强到弱依次为：姜黄素、β‐榄香烯、苦参碱、叶黄素、原花青素、白藜芦醇（P＜0.05）。通过细胞划痕实验发现，6种天然药物均可抑制SRA01／04的迁移（均 P＜0.05），且抑制细胞迁移作用由强到弱依次是：苦参碱、β‐榄香烯、姜黄素、白藜芦醇和叶黄素、原花青素（P＜0.05），其中白藜芦醇与叶黄素的作用强度相近（P＞0.05）。结论天然药物白藜芦醇、叶黄素、苦参碱、原花青素、姜黄素、β‐榄香烯可有效地抑制由bFGF诱导的SRA01／04增殖，并且可抑制该细胞的水平迁移。其中姜黄素和苦参碱分别在抑制SRA01／04增殖及迁移中作用较为突出，可对防治后发性白内障药物的研发提供一定的实验参考。%Objective To examine the inhibitory effects of six natural medicines (resveratrol ,lutein ,matrine ,proanthocyani‐din ,curcumin ,β‐elemene) on the proliferation and migration of human lens epithelial cells and compare their inhibitory intensi‐ty.Methods Cell counting kit‐8 (CCK‐8) assay and scratch‐wound assay were used to quantitatively analyze the effect of the medicines on the proliferation and migration of SRA01/04 cells.Results CCK‐8 assay demonstrated that all the six natural medicines could significantly inhibit the bFGF‐induced proliferation of SRA01/04 cells.The order of proliferation inhibition from strong to weak was curcumin>β‐elemene> matrine> lutein> proanthocyanidin> resveratrol (P<0.05).Scratch‐wound assay showed that all these medicines had the ability to inhibit the migration of SRA01/04 cells (P<0.05) and matrine had the strongest suppressive effect on cell migration ,which was followed byβ‐elemene ,curcumin ,resveratrol ,lutein ,and proanthocya‐nidin (P<0.05).The effect of resveratrol on cell migration was similar to that of lutein (P>0.05).Conclusion The six natu‐ral medicines can effectively inhibit the bFGF‐induced proliferation of SRA01/04 cells and suppress their horizontal migra‐tion.The present study demonstrated the remarkable effects of curcumin and matrine on the proliferation and migration of hu‐man lens epithelial cells ,providing the guidance for developing an effective medicine for prevention and treatment of after‐cata‐ract.